Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- All-Japan Strategy Necessary for Genomic Research: Dr Nakamura
August 2, 2010
- Taiho: Abraxan for Breast Cancer
August 2, 2010
- Pfizer to Begin PIII Trial for Selara for Chronic Heart Failure
August 2, 2010
- AZ: Pulmicort Inhaler for Asthma in Children
August 2, 2010
- RaQualia Begins PI Trial for APA in the US
August 2, 2010
- Nippon Shinyaku: 4-Time Daily Tramal for Cancer Pain
August 2, 2010
- Victoza Improves SBP without Antihypertensives: Novo Nordisk
August 2, 2010
- Korosho Calls on PMDA to Increase Transparency: Mr Nagatsuma
August 2, 2010
- Edoxaban Superior to Enoxaparin in Preventing VTE after TKR: Daiichi Sankyo
August 2, 2010
- PS Dr Adachi Shows Strong Interest in Gov't-Industry Dialogues
August 2, 2010
- S/GSK1349572 Found Effective in Naive HIV Patients in PIIb: Shionogi
August 2, 2010
- JPA to Present Petition Regarding Generic Substitution for Topical Agents
August 2, 2010
- Carna Bio. Signs License Agreement with JHSF for Anticancer Drug Screening Methods
August 2, 2010
- Korosho to Introduce Japanese Version of ACIP
August 2, 2010
- Survey Conducted by OPA Shows Good Compliance
August 2, 2010
- 29 Drugs Including Forteo, Orencia Approved
August 2, 2010
- Livalo to Be Approved in 16 European Countries
August 2, 2010
- Conduct KRAS Gene Testing before First-Line Treatment for CRC: Dr Yoshino of NCC
August 2, 2010
- Celgene Launches Revlimid, Lenadex for Multiple Myeloma
August 2, 2010
- T-DM1 Applied to FDA for Advanced HER2-Positive Breast Cancer: Roche
August 2, 2010
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…